Immune Pharmaceuticals — Investor Presentation (October 2017)
18 slides from Immune Pharmaceuticals's investor presentation, Oct 3, 2017
Slide 1: Immune Pharmaceuticals: Rebuilding with Bertilimumab
IMMUNE PHARMACEUTICALS Rebuilding with Bertilimumab October 2017
Slide 2: Forward Looking Statement
2 This presentation and oral statements made by representatives of the Company may contain projections or other forward - looking statements regarding future events or the future financial performance of the Company . Actual events or results may differ materially from those in the projections or ot
Slide 3: Executive Summary
3 We are focused on immunologic and inflammatory diseases Two active programs generating multiple shots on goal Bertilimumab is a fully human, anti - eotaxin - 1 mAb with applications in a variety of inflammatory diseases Currently running phase 2 trials in bullous pemphigoid (open - label single ar
Slide 4: Focused Pipeline With Multiple Shots on Goal
4 Focused Pipeline With Multiple Shots on Goal Program Indication Preclinical Phase 1 Phase 2 Phase 3 Bertilimumab Bullous Pemphigoid Ongoing Ulcerative Colitis Ongoing Atopic Dermatitis Phase 2 - ready Other inflammatory conditions Phase 2 - ready Nanocyclo Atopic Dermatitis Ongoing Psoriasis Ongoi
Slide 5: Bertilimumab is a First-in-Class Antibody; Eotaxin Implicated in Multiple Diseases
5 Berilimumab is a First - in - Class Antibody Eotaxin - 1 Implicated in Multiple Diseases • Ulcerative Colitis • Crohn ’ s Disease • Inflammatory hepatitis (including NASH) • Gastroenteritis • Asthma • Churg - Strauss Syndrome • Hypereosinophilic syndrome • Bone resorption in rheumatoid arthritis •
Slide 6: Eotaxin-1 Recruits and Activates Eosinophils
6 Eotaxin - 1 (CCL11) is key regulator of tissue eosinophilia, acting as both an eosinophil chemoattractant and a degranulation stimulant First identified as a mediator of allergic airway inflammation Released from epithelial and endothelial cells, fibroblasts, T cells, monocytes, and macrophages Sy
Slide 7: Bertilimumab Blocks Eotaxin-1
7 Bertilimumab (formerly CAT - 213) is a fully human IgG4 antibody High affinity (KD 8.8pM) and specificity for human eotaxin - 1 Does not bind to eotaxin - 2 and - 3 Prevents eotaxin - 1 - induced chemotaxis and shape change of human eosinophils both in vitro and in vivo Good pharmacokinetic profil
Slide 8: Current Clinical Status
8 Current Clinical Status Randomized, double - blind, placebo - controlled (42 subjects) Mayo Disease Index, mucosal injury Ongoing enrollment 7 Israeli & 6 Russian sites Open - label, single - arm (10 - 15 subjects) Safety, BPDAI improvement, and steroid reduction Ongoing enrollment 2 Israeli & 6 U
Slide 9: Bullous Pemphigoid
9 Severe autoimmune skin blistering disease Driven by autoantibodies to BP180 (type XVII collagen) and BP230 ( dystonin ) 30,000 patients in the US and EU ( Orphanet ) Typically treated with prednisone (0.5 - 1.0 mg/kg) Will usually get the disease under control However high prednisone doses increas
Slide 10: Positive Interim Look at Phase 2 Study
10 First 6 subjects of an intended 10 - 15 subjects 85% reduction in BPDAI Total Activity Index (p=0.0096) All subjects achieved a >50% improvement 4/6 with >90% improvement Mean initial prednisone dose was just 26 mg (0.3 mg/kg), tapered to a mean of 9 mg (0.1 mg/kg) by the last assessment (p=0.014
Slide 11: Rapid Improvement Despite Low Prednisone Doses
11 Rapid Improvement Despite Low Prednisone Doses
Slide 12: Case Study: Subject 02-01
12 66 year old white male, newly diagnosed with BP Prior treatment: prednisone 60 mg x 4d, off 2d, 40 mg x 2d, 2 week washout Received 2 bertilimumab infusions The initial protocol - specified regimen, later changed to 3 infusions 95% improvement in BPDAI Total Activity Index from baseline 58 by day
Slide 13: Ulcerative Colitis
13 Over 3.5 million patients with inflammatory bowel disease (IBD) in the US and EU (Kaplan, 2015) Patients with ulcerative colitis (UC) and Crohn’s disease have elevated eotaxin - 1 Half have elevated eotaxin - 1 Eotaxin - 1 strongly implicated as a target in IBD Tissue eotaxin - 1 levels correlate
Slide 14: Bertilimumab Proof of Concept Trial in UC
14 Randomized, double - blind, placebo - controlled trial 42 subjects, 2:1 randomization Patients selected based on Mayo UC Score and eotaxin - 1 levels Sites in Israel (5) and Russia (6) Drug administration on Days 0, 14 and 28; 90 day follow - up Primary endpoint is clinical response (UC Mayo Clin
Slide 15: Path forward in BP: potential move into pivotal phase 2/3 trial
15 In BP, we have potential to move directly into a pivotal phase 2/3 trial Will get FDA feedback from an end - of - phase 2 meeting and SAB input Could target steroid reduction endpoint or go head - to - head against steroids Expect to launch pivotal study in second half of 2018 Development path in
Slide 16: Nanocyclo - Topical Cyclosporine
16 Nanocyclo - Topical Cyclosporine Electron microscopy pictures - Prof.Benita (HUJ) Cyclosporine does not penetrate the skin adequately to treat inflammatory skin diseases Nanocyclo enhances penetration of cyclosporine by formulating it in polymeric nanoparticles Mechanistically similar to topical
Slide 17: New Management and Revised Corporate Strategy
17 New management Elliot Maza, JD, CPA, President and CEO – extensive and successful experience in rebuilding struggling biotech and drug manufacturing companies Tony Fiorino, MD, PhD, CMO/COO – extensive and successful experience in leading clinical stage biotech companies and a former fund manager
Slide 18: Immune Pharmaceuticals Investment Highlights
18 Developing a first - in - class, fully human mAb in phase 2 for two indications Targeting both Orphan and larger indications with unmet medical need Preliminary data from open - label BP trial demonstrated significant reduction in disease activity index (85%) despite aggressive steroid tapering W
Immune Pharmaceuticals — Investor Presentation (October 2017) on 6ix